Characterization of frequently deleted 6q locus in prostate cancer

DNA and Cell Biology

Volumn 25, Issue 11, 2006, Pages 597-607

  Sun, Mei ^a   Srikantan, Vasantha ^a   Ma, Lanfeng ^a   Li, Jia ^a   Zhang, Wei ^b   Petrovics, Gyorgy ^a   Makarem, Mazen ^a   Strovel, Jeffrey W ^f   Horrigan, Stephen G ^f   Augustus, Meena ^f   Sesterhenn, Isabell A ^b   Moul, Judd W ^a,c,d   Chandrasekharappa, Settara ^e   Zou, Zhiqiang ^a   Srivastava, Shiv ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^f Avalon Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CHARCOAL; UNTRANSLATED RNA;

APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL STRAIN LNCAP; CHROMOSOME 6Q; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CHROMOSOME MAP; CHROMOSOME MARKER; CONTROLLED STUDY; CULTURE MEDIUM; DNA SPLICING; GENE EXPRESSION REGULATION; GENE LOCUS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GROWTH INHIBITION; HORMONAL REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN INDUCTION; SERUM; TRANSCRIPTION REGULATION; TRANSCRIPTOMICS; TUMOR SUPPRESSOR GENE;

APOPTOSIS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 6; DIAZONIUM COMPOUNDS; GENE DELETION; GENES, TUMOR SUPPRESSOR; GENETIC MARKERS; HUMANS; LOSS OF HETEROZYGOSITY; MALE; PROSTATIC NEOPLASMS;

EID: 33845319226     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/dna.2006.25.597     Document Type: Article

References (80)

1. ALVAREZ, M., STRASBERG, R.M., and RIEBER, M. (1998). Chromosome-6- mediated suppression of metastatic ability increases basal expression of UV-inducible superoxide dismutase and induction of p53. Int. J. Cancer 77, 586-591.
2. ASKEW, D.S., and XU, F. (1999). New insights into the function of noncoding RNA and its potential role in disease pathogenesis. Histol. Histopathol. 14, 235-241.
3. BOVA, G.S., CARTER, B.S., BUSSEMAKERS, M.J., EMI, M., FUJIWARA, Y., KYPRIANOU, N., JACOBS, S.C., ROBINSON, J.C., EPSTEIN, J.I., and WALSH, P.C. (1993). Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res. 53, 3869-3873.
4. BRUCKHEIMER, E.M., and KYPRIANOU, N. (2000). Apoptosis in prostate carcinogenesis. A growth regulator and a therapeutic target. Cell. Tissue Res. 301, 153-162.
5. BURNSTEIN, K.L. (2005). Regulation of androgen receptor levels: Implications for prostate cancer progression and therapy. J Cell. Biochem. 95, 657-669.
6. BUSSEMAKERS, M.J., VAN BOKHOVEN, A., VERHAEGH, G.W., SMIT, F.P., KARTHAUS, H.F., SCHALKEN, J.A., DEBRUYNE, F.M., RU, N., and ISSACS, W.B. (1999). DD3: A new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 59, 5975-5579.
7. CABEZA-ARVELAIZ, Y., SEPULVEDA, J.L., LEBOVITZ, R.M., THOMPSON, T.C., and CHINAULT, A.C. (2001a). Functional identification of LZTS1 as a candidate prostate tumor suppressor gene on human chromosome 8p22. Oncogene 20, 4169-4179.
8. CABEZA-ARVELAIZ, Y., THOMPSON, T.C., SEPULVEDA, J.L., and CHINAULT, A.C (2001b). LAPSER1: A novel candidate tumor suppressor gene from 10q24.3. Oncogene 20, 6707-6717.
9. CARPTEN, J., NUPPONEN, N., ISAACS, S., SOOD, R., ROBBINS, C., XU, J., FARUQUE, M., MOSES, T., EWING, C., GILLANDERS, E., et al. (2002). Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat. Genet. 30, 181-184.
10. COONEY, K.A., WETZEL, J.C., CONSOLINO, C.M., and WOJNO, K.J. (1996). Identification and characterization of proximal 6q deletions in prostate cancer. Cancer Res. 56, 4150-4153.
11. DAHIYA, R., PERINCHERY, G., DENG, G., and LEE, C. (1998). Multiple sites of loss of heterozygosity on chromosome 8 in human breast cancer has differential correlation with clinical parameters. Int. J. Oncol. 12, 811-816.
12. DE KOK, J.B., VERHAEGH, G.W., ROELOFS, R.W., HESSELS, D., KIEMENEY, L.A., AALDERS, T.W., SWINKELS, D.W., and SCHALKEN, J.A. (2002). DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res. 62, 2695-2698.
13. DONG, J.T. (2006). Prevalent mutations in prostate cancer. J. Cell. Biochem. 97, 433-447.
14. EDDY, S.R. (1999). Noncoding RNA genes. Curr. Opin. Genet. Dev. 9, 695-699.
15. ELGEDAILY, A., BUBENDORF, L., WILLI, N., FU, W., RICHTER, J., MOCH, H., MIHATSCH, M.J., SAUTER, G., and GASSER, T.C. (2001). Discovery of new DNA amplification loci in prostate cancer by comparative genomic hybridization. Prostate 46, 184-190.
16. ESQUELA-KERSCHER, A., and SLACK, F.J. (2006). Oncomirs-microRNAs with a role in cancer. Nat. Rev. Cancer 6, 259-269.
17. FU, X., RAVINDRANATH, L., TRAN, N., PETROVICS, G., and SRIVASTAVA, S. (2006). Regulation of apoptosis by a prostate-specific and prostate cancer-associated noncoding gene, PCGEM1. DNA Cell Biol. 25, 135-141.
18. GRAY, I.C., STEWART, L.M., PHILLIPS, S.M., HAMILTON, J.A., GRAY, N.E., WATSON, G.J., SPURR, N.K., and SNARY, D. (1998). Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN. Br. J. Cancer 78, 1296-1300.
19. HANKINS, G.R., DE SOUZA, A.T., BENTLEY, R.C., PATEL, M.R., MARKS, J.R., IGLEHART, J.D., and JIRTLE, R.L. (1996). M6P/IGF2 receptor: A candidate breast tumor suppressor gene. Oncogene 12, 2003-2009.
20. HAO, Y., CRENSHAW, T., MOULTON, T., NEWCOMB, E., and TYCKO, B. (1993). Tumour-suppressor activity of H19 RNA. Nature 365, 764-767.
21. HESSELS, D., KLEIN GUNNEWIEK, J.M., VAN OORT, I., KARTHAUS, M., VAN LEENDERS, G.J., VAN BALKEN, B., KIEMENEY, L.A., WITJES, J.A., and SCHALKEN, J.A. (2003). DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur. Urol. 44, 8-15.
22. HIBI, K., NAKAMURA, H., HIRAI, A., FUJIKAKE, Y., KASAI, Y., AKIYAMA, S., ITO, K., and TAKAGI, H. (1996). Loss of H19 imprinting in esophageal cancer. Cancer Res. 56, 480-482.
23. HILDEBRANDT, T., PREIHERR, J., TAREE, N., KLOSTERMANN, S., VAN MUIJEN, G.N., and WEIDLE, U.H. (2000). Identification of THW, a putative new tumor suppressor gene. Anticancer Res. 20, 2801-2809.
24. HYYTINEN, E.R., THALMANN, G.N., ZHAU, H.E., KARHU, R., KALLIONIEMI, O.P., CHUNG, L.W., and VISAKORPI, T. (1997). Genetic changes associated with the acquisition of androgen-independent growth, tumorigenicity and metastatic potential in a prostate cancer model. Br. J. Cancer 75, 190-195.
25. HYYTINEN, E.R., FRIERSON, H.F., Jr., BOYD, J.C., CHUNG, L.W., and DONG, J.T. (1999). Three distinct regions of allelic loss at 13q14, 13q21-22, and 13q33 in prostate cancer. Genes Chromosomes Cancer 25, 108-114.
26. HYYTINEN, E.R., SAADUT, R., CHEN, C., PAULL, L., KOIVISTO, P.A., VESSELLA, R.L., FRIERSON, H.F., Jr., and DONG, J.T. (2002). Defining the region(s) of deletion at 6q16-q22 in human prostate cancer. Genes Chromosomes Cancer 34, 306-312.
27. JEMAL, A., SIEGEL, R., WARD, E., MURRAY, T., XU, J., SMIGAL, C., and THUN, M.J. (2006). Cancer statistics. CA Cancer J. Clin. 56, 106-130.
28. KAMMERER, S., ROTH, R.B., RENELAND, R., MARNELLOS, G., HOYAL, C.R., MARKWARD, N.J., EBNER, F., KIECHLE, M., SCHWARZ-BOEGER, U., GRIFFITHS, L.R., et al. (2004). Large-scale association study identifies ICAM gene region as breast and prostate cancer susceptibility locus. Cancer Res. 64, 8906-8910.
29. KELLEY, R.L., and KURODA, M.I. (2000). Noncoding RNA genes in dosage compensation and imprinting. Cell 103, 9-12.
30. KIBEL, A.S., SCHUTTE, M., KERN, S.E., ISAACS, W.B., and BOVA, G.S. (1998). Identification of 12p as a region of frequent deletion in advanced prostate cancer. Cancer Res. 58, 5652-5655.
31. KONDO, M., SUZUKI, H., UEDA, R., OSADA, H., TAKAGI, K., TAKAHASHI, T., and TAKAHASHI, T. (1995). Frequent loss of imprinting of the H19 gene is often associated with its overexpression in human lung cancers. Oncogene 10, 1193-1198.
32. KONISHI, N., NAKAMURA, M., KISHI, M., ISHIDA, E., SHIMADA, K., MATSUYOSHI, S., NAGAI, H., and EMI, M. (2003). Genetic mapping of allelic loss on chromosome 6q within heterogeneous prostate carcinoma. Cancer Sci. 94, 764-768.
33. LATIL, A., BARON, J.C., CUSSENOT, O., FOURNIER, G., SOUSSI, T., BOCCON-GIBOD, L., LE DUC, A., ROUESSE, J., and LIDEREAU, R. (1994). Genetic alterations in localized prostate cancer: Identification of a common region of deletion on chromosome arm 18q. Genes Chromosomes Cancer 11, 119-125.
34. LEE, J.H., and WELCH, D.R. (1997). Suppression of metastasis in human breast carcinoma MDA-MB-435 cells after transfection with the metastasis suppressor gene, KiSS-1. Cancer Res. 57, 2384-2387.
35. LI, J., YEN, C., LIAW, D., PODSYPANINA, K., BOSE, S., WANG, S.I., PUC, J., MILIARESIS, C., RODGERS, L., MCCOMBIE, R., et al. (1997). PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943-1947.
36. MATSUDA, K., MATSUYAMA, H., HARA, T., YOSHIHIRO, S., OGA, A., KAWAUCHI, S., FURUYA, T., IZUMI, H., NAITO, K., and SASAKI, K. (2004). DNA sequence copy number aberrations in prostate cancers: A comparison of comparative genomic hybridization data between Japan and European countries. Cancer Genet. Cytogenet. 152, 119-123.
37. MIELE, M.E., JEWETT, M.D., GOLDBERG, S.F., HYATT, D.L., MORELLI, C., GUALANDI, F., RIMESSI, P., HICKS, D.J., WEISSMAN, B.E., BARBANTI-BRODANO, G., et al. (2000). A human melanoma metastasis-suppressor locus maps to 6q16.3-q23. Int. J. Cancer 86, 524-528.
38. MEIER, C., HERKOMMER, K., HOEGEL, J., VOGEL, W., and PAISS, T. (2005). A genomewide linkage analysis for prostate cancer susceptibility genes in families from Germany. Eur. J. Hum. Genet. 13, 352-360.
39. MILLIKIN, D., MEESE, E., VOGELSTEIN, B., WITKOWSKI, C., and TRENT, J. (1991). Loss of heterozygosity for loci on the long arm of chromosome 6 in human malignant melanoma. Cancer Res. 51, 5449-5453.
40. MORITA, R., SAITO, S., ISHIKAWA, J., OGAWA, O., YOSHIDA, O., YAMAKAWA, K., and NAKAMURA, Y. (1991). Common regions of deletion on chromosomes 5q, 6q, and 10q in renal cell carcinoma. Cancer Res. 51, 5817-5820.
41. NARLA, G., HEATH, K.E., REEVES, H.L., LI, D., GIONO, L.E., KIMMELMAN, A.C., GLUCKSMAN, M.J., NARLA, J., ENG, F.J., CHAN, A.M., et al. (2001). KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science 294, 2563-2566.
42. NEGRINI, M., SABBIONI, S., POSSATI, L., RATTAN, S., CORALLINI, A., BARBANTI-BRODANO, G., and CROCE, C.M. (1994). Suppression of tumorigenicity of breast cancer cells by microcell-mediated chromosome transfer: studies on chromosomes 6 and 11. Cancer Res. 54, 1331-1336.
43. NUPPONEN, N.N., and CARPTEN, J.D. (2001). Prostate cancer susceptibility genes: Many studies, many results, no answers. Cancer Metastasis Rev. 20, 155-164.
44. NUPPONEN, N.N., and VISAKORPI, T. (2000). Molecular cytogenetics of prostate cancer. Microsc. Res. Technol. 51, 456-463.
45. NUPPONEN, N.N., HYYTINEN, E.R., KALLIONIEMI, A.H., and VISAKORPI, T. (1998). Genetic alterations in prostate cancer cell lines detected by comparative genomic hybridization. Cancer Genet. Cytogenet. 101, 53-57.
46. ORPHANOS, V., McGOWN, G., HEY, Y., BOYLE, J.M., and SANTIBANEZ-KOREF, M. (1995). Proximal 6q, a region showing allele loss in primary breast cancer. Br. J. Cancer 71, 290-293.
47. PETROVICS, G., ZHANG, W., MAKAREN, M., STREET, J.P., CONNELLY, R., SUN, L., SESTERHENN, I.A., SRIKANTAN, V., MOUL, J.W., and SRIVASTAVA, S. (2004). Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. Oncogene 23, 605-611.
48. PETROVICS, G., LIU, A., SHAHEDUZZAMAN, S., FURUSATO, B., SUN, C., CHEN, Y., NAU, M., RAVINDRANATH, L., CHEN, Y., DOBI, A., SRIKANTAN, V., SESTERHENN, I.A., MCLEOD, D.G., VAHEY, M., MOUL, J.W., and SRIVASTAVA, S. (2005). Frequent overexpression of ETS related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 24, 3847-3852.
49. QUEIMADO, L., REIS, A., FONSECA, I., MARTINS, C., LOVETT, M., SOARES, J., and PARREIRA, L. (1998). A refined localization of two deleted regions in chromosome 6q associated with salivary gland carcinomas. Oncogene 16, 83-88.
50. ROKMAN, A., BAFFOE-BONNIE, A.B., GILLANDERS, E., FREDRIKSSON, H., AUTIO, V., IKONEN, T., GIBBS, K.D., JR., JONES, M., GILDEA, D., FREASLUTZ, D., et al. (2005). Hereditary prostate cancer in Finland: Fine-mapping validates 3p26 as a major predisposition locus. Hum. Genet. 116, 43-50.
51. SANDHU, A.K., HUBBARD, K., KAUR, G.P., JHA, K.K., OZER, H.L., and ATHWAL, R.S. (1994). Senescence of immortal human fibroblasts by the introduction of normal human chromosome 6. Proc. Natl. Acad. Sci. USA 91, 5498-5502.
52. SANDHU, A.K., KAUR, G.P., REDDY, D.E., RANE, N.S., and ATHWAL, R.S. (1996). A gene on 6q 14-21 restores senescence to immortal ovarian tumor cells. Oncogene 12, 247-252.
53. SATO, K., QIAN, J., SLEZAK, J.M., LIEBER, M.M., BOSTWICK, D.G., BERGSTRALH, E.J., and JENKINS, R.B. (1999). Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J. Natl. Cancer Inst. 91, 1574-1580.
54. SHEN, M.M., and ABATE-SHEN, C. (2003). Roles of the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis. Dev. Dyn. 228, 767-778.
55. SHIRASAKI, F., TAKATA, M., HATTA, N., and TAKEHARA, K. (2001). Loss of expression of the metastasis suppressor gene KiSS1 during melanoma progression and its association with LOH of chro-mosome 6q16.3-q23. Cancer Res. 61, 7422-7425.
56. SLACK, F.J., and WEIDHAAS, J.B. (2006). MicroRNAs as a potential magic bullet in cancer. Future Oncol. Feb 2, 73-82.
57. SRIKANTAN, V., SESTERHENN, I.A., DAVIS, L., HANKINS, G.R., AVALLONE, F.A., LIVEZEY, J.R., CONNELLY, R., MOSTOFI, F.K., MCLEOD, D.G., MOUL, J.W., et al. (1999). Allelic loss on chromosome 6Q in primary prostate cancer. Int. J. Cancer 84, 331-335.
58. SRIKANTAN, V., ZOU, Z., PETROVICS, G., XU, L., AUGUSTUS, M., DAVIS, L., LIVEZEY, J.R., CONNELL, T., SESTERHENN, I.A., YOSHINO, K., et al. (2000). PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. Proc. Natl. Acad. Sci. USA 97, 12216-12221.
59. STROHMEYER, D.M., BERGER, A.P., MOORE, D.H., 2ND, BARTSCH, G., KLOCKER, H., CARROLL, P.R., LOENING, S.A., and JENSEN, R.H. (2004). Genetic aberrations in prostate carcinoma detected by comparative genomic hybridization and microsatellite analysis: association with progression and angiogenesis. Prostate 59, 43-58.
60. SUN, M., MA, L., XU, L., LI, J., ZHANG, W., PETROVICS, G., MAKAREM, M., SESTERHENN, I., ZHANG, M., MOUL, J., SRIVASTAVA, S., and ZOU, Z. (2002). A human gene DERPC on 16 q22.1 inhibits prostate tumor cell growth and its expression is decreased in prostate and renal tumors. Mol. Med. 8, 655-663.
61. SUZUKI, H., KOMIYA, A., EMI, M., KURAMOCHI, H., SHIRAISHI, T., YATANI, R., and SHIMAZAKI, J. (1996). Three distinct commonly deleted regions of chromosome arm 16q in human primary and metastatic prostate cancers. Genes Chromosomes Cancer 17, 225-233.
62. SZYMANSKI, M., BARCISZEWSKA, M.Z., ERDMANN, V.A., and BARCISZEWSKI, J. (2005). A new frontier for molecular medicine: Noncoding RNAs. Biochim. Biophys. Acta 25, 65-75.
63. SZYMANSKI, M., and BARCISZEWSKI, J. (2006). RNA regulation in mammals. Ann. NY Acad. Sci. 1067, 461-468.
64. TAKEDA, K., ICHIJO, H., FUJII, M., MOCHIDA, Y., SAITOH, M., NISHITOH, H., SAMPATH, T.K., and MIYAZONO, K. (1998). Identification of a novel bone morphogenetic protein-responsive gene that may function as a noncoding RNA. J. Biol. Chem. 273, 17079-17085.
65. TAVTIGIAN, S.V., SIMARD, J., TENG, D.H., ABTIN, V., BAUMGARD, M., BECK, A., CAMP, N.J., CARILLO, A.R., CHEN, Y., DAYANANTH, P., et al. (2001). A candidate prostate cancer susceptibility gene at chromosome 17p. Nat. Genet. 27, 172-180.
66. THEILE, M., SEITZ, S., ARNOLD, W., JANDRIG, B., FREGE, R., SCHLAG, P.M., HAENSCH, W., GUSKI, H., WINZER, K.J., BARRETT, J.C., et al. (1996). A defined chromosome 6q fragment (at D6S310) harbors a putative tumor suppressor gene for breast cancer. Oncogene 13, 677-685.
67. TINZL, M., MARBERGER, M., HORVATH, S., and CHYPRE, C. (2004), DD3PCA3 RNA analysis in urine - A new perspective for detecting prostate cancer. Eur. Urol. 46, 182-186.
68. TOMLINS, S.A., RHODES, D.R., PERNER, S., DHANASEKARAN, S.M., MEHRA, R., SUN, X.W., VARAMBALLY, S., CAO, X., TCHINDA, J., KUEFER, R., LEE, C., MONTIE, J.E., SHAH, R.B., PIENTA, K.J., RUBIN, M.A., and CHINNAYAN, A.M. (2005). Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644-647.
69. TRENT, J.M., STANBRIDGE, E.J., MCBRIDE, H.L., MEESE, E.U., CASEY, G., ARAUJO, D.E., WITKOWSKI, C.M., and NAGLE, R.B. (1990). Tumorigenicity in human melanoma cell lines controlled by introduction of human chromosome 6. Science 247, 568-571.
70. VERHAGEN, P.C., HERMANS, K.G., BROK, M.O., VAN WEERDEN, W.M., TILANUS, M.G., DE WEGER, R.A., BOON, T.A., and TRAPMAN, J. (2002). Deletion of chromosomal region 6q14-16 in prostate cancer. Int. J. Cancer 102, 142-147.
71. VOELLER, H.J., AUGUSTUS, M., MADIKE, V., BOVA, G.S., CARTER, K.C., and GELMANN, E.P. (1997). Coding region of NKX3.1, a prostate-specific homeobox gene on 8p21, is not mutated in human prostate cancers. Cancer Res. 57, 4455-4459.
72. VAN DEKKEN, H., PARIS, P.L., ALBERTSON, D.G., ALERS, J.C., ANDAYA, A., KOWBEL, D., VAN DER KWAST, T.H., PINKEL, D., SCHRODER, F.H., VISSERS, K.J., et al. (2004). Evaluation of genetic patterns in different tumor areas of intermediate-grade prostatic adenocarcinomas by high-resolution genomic array analysis. Genes Chromosomes Cancer 39, 249-256.
73. WAN, M., SUN, T., VYAS, R., ZHENG, J., GRANADA, E., and DUBEAU, L. (1999). Suppression of tumorigenicity in human ovarian cancer cell lines is controlled by a 2 cM fragment in chromosomal region 6q24-q25. Oncogene 18, 1545-1551.
74. WELCH, D.R., CHEN, P., MIELE, M.E., MCGARY, C.T., BOWER, J.M., STANBRIDGE, E.J., and WEISSMAN, B.E. (1994). Microcell-mediated transfer of chromosome 6 into metastatic human C8161 melanoma cells suppresses metastasis but does not inhibit tumorigenicity. Oncogene 9, 255-262.
75. XU, J., ZHENG, S.L., CARPTEN, J.D., NUPPONEN, N.N., ROBBINS, C.M., MESTRE, J., MOSES, T.Y., FAITH, D.A., KELLY, B.D., ISAACS, S.D., et al. (2001). Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer. Am. J. Hum. Genet. 68, 901-911.
76. XU, J., ZHENG, S.L., KOMIYA, A., MYCHALECKYJ, J.C., ISAACS, S.D., HU, J.J., STERLING, D., LANGE, E.M., HAWKINS, G.A., TURNER, A., et al. (2002). Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet. 32, 321-325.
77. XU, L.L., SRIKANTAN, V., SESTERHENN, I.A., AUGUSTUS, M., DEAN, R., MOUL, J.W., CARTER, K.C., and SRIVASTAVA, S. (2000). Expression profile of an androgen regulated prostate specific homeobox gene NKX3.1in primary prostate cancer. J. Urol. 163, 972-979.
78. ZENKLUSEN, J.C., THOMPSON, J.C., TRONCOSO, P., KAGAN, J., and CONTI, C.J. (1994). Loss of heterozygosity in human primary prostate carcinomas: A possible tumor suppressor gene at 7q31.1. Cancer Res. 54, 6370-6373.
79. ZHANG, M.Q. (1998). Statistical features of human exons and their flanking regions. Hum. Mol. Genet. 7, 919-932.
80. ZOU, Z., ANISOWICZ, A., HENDRIX, M.J., THOR, A., NEVEU, M., SHENG, S., RAHDI, K., SEFTOR, E., and SAGER, R. (1994). Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 263, 526-529.